Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05041530

Abdominal Wall Closure After Laparotomy in Oncologic Surgery

The REBUILD Study is a first-in-human evaluation of the safety and performance of REBUILD Bioabsorbable.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinica Medellin, Medellín, Antioquia, Colombia

Loading trial locations.

About this study

REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures. In this study, REBUILD will be used in oncology patients undergoing an open, elective, intent-to-cure, laparotomy procedure. The study is a prospective, non-randomized, multi-center study designed to generate descriptive data about the use of REBUILD. The primary safety outcome is reported device-related adverse events. The primary performance outcome is the integrity of the abdominal wall over one year assessed by clinical examination of the abdomen. If available, CT studies performed within 12 months post-procedure will be used to confirm apposition of the medial border of the rectus muscles and integrity of the abdominal wall.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is 18-75 years of age
  • Patient is scheduled for oncologic, open, elective, intent-to-cure laparotomy
  • Patient is able to provide written informed consent
  • Patient is able and willing to comply with all study requirements

Exclusion criteria

  • Patient is scheduled for a palliative procedure
  • Patient has had previous failed surgical repair of a ventral or incisional hernia
  • Patient has a current infection at the intended surgical site
  • Patient is participating in a concurrent investigational medical device study
  • Patient is pregnant or planning on becoming pregnant during the study period
  • Patient has a history of psychological condition, drug or alcohol misuse which may interfere with their ability to be compliant with post-operative visits.

Treatment and study plan

REBUILD Bioabsorbable

Device

REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures.

Primary outcomes

  1. Adverse Events

    Time frame: 12 months

    The number of device-related adverse events

  2. Performance

    Time frame: 12 months

    The number of subjects with abdominal wall integrity at 3-, 6-, and 12-months post-surgery. Abdominal wall integrity will be assessed via clinical examination of the abdomen to identify a fascial defect, bulge, reducible palpable mass, or discomfort with a cough impulse. Standard of care CT or MR imaging that is performed within 12 months of the surgery will be evaluated to confirm apposition of the medial border of the rectus abdominis muscles and integrity of the abdominal wall.

Study contacts

Contact information is provided by the study sponsor or research team.

Daniel Jacobs, MD

CONTACT

[email protected]

650-303-6140

Kathryn Kelley, BSN

CONTACT

[email protected]

925-350-5173

Sponsors and collaborators

Lead sponsor

AbSolutions Med Inc.

Industry

Collaborators

  • Cogent Technologies Corporation

Registry information

Official study title

A Prospective, Multi-Center, Single Arm, Feasibility Study Using REBUILD Bioabsorbable™ for Closure of the Abdominal Wall After Oncologic Laparotomy

Acronym: REBUILD

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Sep 13, 2021
Registry last updated
Dec 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.